Medtech1.com: Great Information, Real Community, Better Living.
 Register
 Login
 Main Page
 MedTech News
Tech & Innovation
Living With a Device
 Education Center
Diagnostic Tests
Conditions
Procedures
Women's Health
Companies
Online Resources
Video Library
Dr. Christopher Kwolek  MedTech  Hero™
Dr. Christopher Kwolek:
Pioneering New Blood Clot Treatments.
About Heroes
 Join the Discussion in  Our Forums
 Community
MedTech1 Forums
 Advocacy Center
Contact Congress
Find a Patient Group
 Bookmark Us
 
advertisement
Search the Body1 Network
August 08, 2020  
MEDTECH NEWS: Technology & Innovation

  • Print this Article
  • Email this Article
  • Links/Reprints
  • New Drug for Leukemia Patients

    New Drug for Leukemia Patients


    April 21, 2005

    By: Hannah Clark for Medtech1


    A new drug that could help leukemia patients has successfully completed a Phase 1 clinical trial.

    The drug, BMS-354825, helps patients with chronic myelogenous leukemia (CML) who have developed resistance to Gleevec, a highly successful medication that was approved by the U.S. Food and Drug Administration in 2001.

    Learn More
    For more information on leukemia, visit:

    Leukemia & Lymphoma Society

    Leukemia Research Foundation

    National Cancer Institute

    For more information on the drug’s clinical trial, click here

    Unlike chemotherapy, Gleevec targets the cancer-causing enzyme without affecting healthy cells. Previously, a CML patient’s only options were a bone transplant or Interferon, a drug that prolonged life but caused unpleasant side effects.

    Every year, however, approximately 4 percent of patients develop resistance to Gleevec because of mutations in the enzyme that causes CML. The new drug helps patients with 30 out of 31 of the known mutations. The remaining mutation, unfortunately, causes 20 percent of the resistant cases.

    According to researchers, 86 percent of the patients treated with the new drug, developed by Bristol-Myers Squibb, achieved complete hematologic remission, which means their blood counts returned to normal. The disease cannot actually be cured, but it can be managed if patients continue to take medication.

    Chronic myelogenous leukemia (CML), which starts in the bone marrow and spreads to the blood, was the cause of death for 1,570 Americans in 2004, according to the American Cancer Society.

    Another drug that shows promise for Gleevec-resistant CML, AMN107, is in earlier stages of development. Novartis, which manufactures Gleevec, is also the company behind AMN107.

    “The good news for people is there are now two really good looking prospects that are coming out at the same time,” said Dr. Charles Sawyers, one of the leaders of the BMS-354825 research team, who works out of the University of California Los Angeles, and is employed by the Howard Hughes Medical Institute.

    Dr. Sawyers and Dr. Moshe Talpaz of the University of Texas recently presented their findings at the annual conference of the American Society of Hematology.

    While Phase 1 clinical trial results are often very preliminary, researchers say the BMS-354825 results are significant enough to merit close attention.

    “It’s very unusual, but it’s very much the way Gleevec was,” said Dr. Alan Kinniburgh, senior vice president for research at the Leukemia and Lymphoma Society.

    “The science behind it is spectacular, plus it is following in the footsteps of a really successful drug,” said Dr. Brian Druker of the Oregon Health & Science University Cancer Institute, whose work led to the development of Gleevec.

    Patients with Gleevec-resistant CML will be the first to benefit from the new drug. Ultimately, however, doctors say BMS-354825 may be used in combination with Gleevec before the cancer-causing cells have been given any chance to mutate.

    Both of the new drugs are more potent than Gleevec, so they could cause the cancer to go into deeper remission.

    While some drugs require Phase 3 trials before FDA approval, Dr. Kinniburgh expects a successful Phase 2 trial will be sufficient for BMS-354825, which means the drug could be on the market within two years. He noted that Gleevec was approved based on a 53-patient Phase 2 trial.

    “I would be shocked if a Phase 2 trial weren’t the basis for approval of the drug,” he said.

    Last updated: 21-Apr-05

    Comments

  • Add Comment
  •    
    Interact on Medtech1

    Discuss this topic with others.
     
    Feature Archives

    Web Technology to Offer Further Mental Health Support

    Sweat Powers Tattoo Biobatteries While You Exercise

    Activity Trackers Could be Beneficial for Older Adults

    Diseases Diagnosed by 'Smart' Holograms

    Fruit flies make good stand-ins for humans in diabetes treatment tests

    Next 5 Features ...

    More Features ...
       
     
     
    Related Content
    Leukemia

    Hodgkin's Disease

    Hepatitis (Chronic and Acute)

    Boston Wins

    Jeanne Carmen, Darling of the 1950s, Dies

    More Features ...
     
    Home About Us Press Jobs Advertise With Us Contact Us
    advertisement
    © 2020 Body1 All rights reserved.
    Disclaimer: The information provided within this website is for educational purposes only and is not a substitute for consultation with your physician or healthcare provider. The opinions expressed herein are not necessarily those of the Owners and Sponsors of this site. By using this site you agree to indemnify, and hold the Owners and Sponsors harmless, from any disputes arising from content posted here-in.